Todos Med Ltd (TOMDF)

[JoeForkeyBolo]

Pennyes, your info is a little outdated. Todos Medical is a completely separate company than Amarantus Biosciences (AMBS), not a subsidiary. Todos Medical is based in Israel but has an office in New York City.

In December 2018, Todos and Amarantus partnered to form Breakthrough Diagnostics to focus on further development of the LymPro blood test.

https://investor.todosmedical.com/news-events/press-releases/detail/10/todos-medical-enters-into-joint-venture-agreement-with

In June 2020 Todos completed the acquisition of the Breakthrough Diagnostics joint venture and took sole ownership of LymPro. This acquisition awarded Amarantus 78 Million shares of Todos Medical. At the time the accounted for 49% of the outstanding TOMDF shares.

https://investor.todosmedical.com/news-events/press-releases/detail/62/todos-medical-completes-acquisition-of-breakthrough

However, during the remainder of 2020 and 2021, Todos issued more shares to fund operations, trials, research, and transferring all existing convertible debt to a handful of reputable venture capital firms who were committed to the long-term growth and eventual uplist to NASDAQ. As more shares were issued, the 49% value dropped. At current TOMDF share count, the 78 Million shares owned by Amarantus is approximately 8.3% of the outstanding shares.

Todos Medical began in Israel in 2010 and is not related to the Amarantus corporate structure in any way other than the joint venture and acquisition of Breakthrough Diagnostics as described above. They both had the same CEO until Gerald stepped down from Amarantus and an interim CEO was announced until a new CEO can be hired. Gerald has been focused on Todos but his plan is that once Todos uplists to NASDAQ then Amarantus will have the ability to sell their Todos shares to pay off debt and fund continued operations of the assets they still hold. This would be a rebirth of Amarantus and seems like a good plan as long as Todos executes well on their plan.

Amarantus Biosciences and Todos Medical are completely separate companies except for the paths crossing as mentioned above. Todos had a number of diagnostic tests in the works prior to involvement with Amarantus and acquired the Videssa breast cancer test with the acquisition of Provista Labs. Amarantus had nothing to do with that transaction.